Biocon Shares Surge 6% as Mylan Prepares to Exit Drugmaker Following Rs 3,481 Crore Stake Sale
In a significant market development, Biocon’s shares surged over 6% on Tuesday, nearing a peak not seen in 18 months. This market movement is largely attributed to Viatris-owned Mylan’s announcement of a divestiture of up to 9.2 crore shares valued at approximately Rs 3,481 crore, which corresponds to a 5.64% stake in the Indian pharmaceutical company. The share price increased to Rs 436.15, suggesting strong market sentiment surrounding the stock, especially as it could mark Biocon’s most robust trading day since January 2025.
Mylan has set a floor price for the stake sale at Rs 378.50 per share, which positions the offering at an approximate 8% discount to Biocon’s previous closing price of Rs 410.95. Preliminary trading activity indicates that around 9 crore shares were transacted in block deals, closely aligning with the volume anticipated from Mylan’s stake. This transactional activity indicates heightened investor interest, albeit with the identity of the seller in the early transactions remaining unclear, emphasizing the dynamic nature of this event.
As of March 31, 2026, Biocon’s shareholding structure reveals that significant stakeholders include Mylan (5.64%), promoter Kiran Mazumdar Shaw (30%), and Glentec International (15%). Additionally, approximately 39 mutual funds possess over 15% of the company’s equity, while insurance companies account for more than 6%. Retail participation is notable with around 3.74 lakh shareholders collectively holding a 6% stake, highlighting a diverse ownership spectrum that could influence future strategic directions for Biocon.
Market performance metrics indicate a generally positive outlook for Biocon, with shares having appreciated by around 12% year-to-date and approximately 14% over the past year. Longer-term gains illustrate the drugmaker’s resilience, with 66% returns recorded over three years. Given the recent surge in share price and active trading, investors may want to closely monitor forthcoming developments as Mylan moves to offload its stake, which could further shape Biocon’s market narrative in the upcoming quarters.
Source: The Economic Times
(Expert Note: This report was prepared by the Wealthova team.)